ReviewiScience2026
Vestibular disorders and monoamine neurotransmitters: Current evidence.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vestibular system, a crucial sensorimotor apparatus for balance and spatial orientation, is regulated by neurotransmitters. Despite its essential function, the intricacies of neurotransmission within this system, particularly regarding monoamine neurotransmitters, remain not fully explained. A variety of vestibular disorders and therapeutic interventions are associated with balance regulation, underscoring the significance of understanding the neurotransmission in the vestibular system. This comprehensive review offers an overall insight into the role of monoamine neurotransmitters, including serotonin (5-HT), histamine, dopamine, and norepinephrine (NE), in the vestibular compensation following peripheral vestibular dysfunction. By examining the existing literature and integrating recent findings, monoamine neurotransmitters are closely associated with vestibular disorders, and their modulators have been used in the treatment of such conditions. Based on the vestibular dysfunction, we highlight the expression and functional significance of these neurotransmitters in the early vestibular compensation. Future research will further explore the role of neurotransmitters and their receptors in vestibular compensation, providing new ideas for the development of more effective treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.